Table 1.
Baseline characteristics of the BioAF cohort (n = 241).
| LVA | p-value | Recurrences | p-value | |||
|---|---|---|---|---|---|---|
| Yes (n = 65) | No (n = 176) | Yes (n = 62) | No (n = 179) | |||
| Age, years | 69 (64–75) | 63 (55–71) | <0.001 | 64 (56–69) | 65 (58–73) | 0.112 |
| Females | 55 | 35 | 0.005 | 40 | 38 | 0.763 |
| Persistent AF | 82 | 51 | <0.001 | 68 | 54 | 0.044 |
| Electro-anatomical substrate | — | — | — | 36 | 21 | 0.024 |
| eGFR, ml/min/1.73 m2 | 68 (57–82) | 79 (68–93) | <0.001 | 79 (66–89) | 76 (63–89) | 0.390 |
| BMI, kg/m2 | 30 (26–33) | 29 (26–33) | 0.255 | 31 (27–34) | 28 (26–33) | 0.025 |
| LA diameter, mm | 42 (45–49) | 43 (39–48) | 0.028 | 45 (39–48) | 44 (40–48) | 0.765 |
| EF, % | 60 (50–65) | 58 (50–65) | 0.785 | 60 (50–65) | 59 (50–65) | 0.694 |
| CHA2DS2-VASc score | 3 (3–4) | 2 (1–4) | <0.001 | 3 (1–4) | 3 (1–4) | 0.996 |
| APPLE score | 3 (2–4) | 2 (1–2) | <0.001 | 2 (1–3) | 2 (1–3) | 0.579 |
| DR-FLASH score | 5 (4–5) | 3 (2–4) | <0.001 | 4 (3–5) | 4 (2–5) | 0.214 |
| MB-LATER score | 2 (1–3) | 2 (1–2) | 0.053 | 2 (1–3) | 2 (1–3) | 0.018 |
| Recurrences | 22 (34) | 37 (21) | 0.024 | — | — | — |
Data presented as mean (IQR) or %.
Abbreviations: LVA – low voltage areas; AF – atrial fibrillation; BMI – body mass index; eGFR – estimated glomerular filtration rate; LA – left atrial; EF – ejection fraction; CHA2DS2-VASc score – congestive heart failure, hypertension, age ≥75 y, diabetes, stroke/thromboembolism, vascular disease (s), age 65–74 y, females; APPLE score – Age > 65 years, Persistent AF, imPaired eGFR (<60 ml/min/1.73 m2), LA diameter ≥43 mm, EF <50%; DR-FLASH score – diabetes mellitus, renal dysfunction, persistent form of AF, LA diameter >45 mm, age >65 years, female sex, and hypertension; MB-LATER score – Male gender, Bundle branch block or QRS >120 ms, LA diameter ≥47 mm, AF Type (persistent AF), Early Recurrence <3 months.